Supernus Pharmaceuticals, Inc. has disclosed a significant transaction involving restricted stock units (RSUs) for its Senior Vice President and Chief Financial Officer, Timothy C. Dec. This move is part of the company’s broader strategy as it prepares for its merger with Indivior Pharmaceuticals, Inc., which is expected to enhance its market position.

The filing, made on November 2, 2026, indicates that Dec received 70,000 RSUs, which will vest in installments over the next few years. Notably, 50% of these RSUs will vest upon the completion of the merger, with additional portions vesting at one, two, and three years after the merger closes. This compensation structure aligns Dec’s interests with the long-term success of the combined entity.

Background

Supernus Pharmaceuticals, Inc. operates in the pharmaceutical preparations industry, classified under SIC code 2834. The company trades on the Nasdaq under the ticker symbol SUPN. Established as a large accelerated filer, Supernus has been actively involved in the development of innovative therapies for central nervous system disorders.

What the Filing Says

The SEC filing indicates that Dec’s transaction took place on October 30, 2026, and that the RSUs are set to be settled in common stock upon vesting. According to the filing, “These restricted stock units are settled in common stock upon vesting, which occurs in four installments.” This structure is designed to incentivize performance and align executive compensation with shareholder interests.

Impact

This transaction may affect several stakeholders within the company, including shareholders and employees. By tying executive compensation to the success of the merger, Supernus aims to ensure that its leadership is motivated to drive the company forward during this transitional period. The merger with Indivior is expected to create a more robust portfolio of products and enhance competitive positioning in the pharmaceutical market.

What's Next

The filing does not say what happens next. However, as the merger progresses, further disclosures and filings are likely to follow, detailing the integration of operations and any additional compensation arrangements for executives.